Fluconazole Versus Micafungin in Neonates With Candidiasis (NCT02145832) | Clinical Trial Compass
CompletedPhase 2/3
Fluconazole Versus Micafungin in Neonates With Candidiasis
Belgium, France, Italy100 participantsStarted 2014-10
Plain-language summary
This study is designed to determine whether micafungin is as efficacious as the current standard of fluconazole, to compare the safety of the two drugs in the treatment of proven neonatal candidiasis.
It is also designed to further elucidate the pharmacokinetics of the two products in the growing and developing neonate and premature infant.
Who can participate
Age range24 Weeks – 42 Weeks
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Neonates and infants between 24 up to 42 weeks gestational age AND with a post-natal age of 48 hours of life up to day of life (DOL) 120 at the time of culture acquisition.
✓. Requiring antifungal therapy according to medical decision by the attending physician for microbiologically documented or clinically suspected candida infection independently from the availability of any positive culture for Candida spp
✓. Written informed consent from the parents or the legally authorized representative must be obtained prior to entry.
✓. Infant must have sufficient venous access to permit administration of study medication and monitoring of safety variables.
✓. And specifically for the French participants: infant shall be insured (Health Insurance) - able to understand and accept the study constraints
Exclusion criteria
✕. Infant exposed to fluconazole or micafungin prophylaxis prior to inclusion
✕. Infant who has received more than 48 hours of systemic antifungal therapy (any product) prior to the first dose of study drug for treatment of the current Candida infection.
✕. Infant with a concomitant medical condition, whose participation, in the opinion of the Investigator and/or medical advisor, may create an unacceptable additional risk.
✕. Infant previously enrolled in this study.
✕. Infant who is co-infected with a non-Candida fungal organism.
What they're measuring
1
Area Under the Concentration / Minimal Inhibitory Concentration ratio (AUC/MIC ratio)